Fig. 4.

The effects of monoclonal antibody (mAb) Terasaki Foundation Laboratory (TFL)-007s on the secretion of primary and secondary allo-human leucocyte antigen (HLA) class II immunoglobulin (Ig)G antibodies by activated B lymphocytes obtained from an alloimmunized woman. TFL-007s was used at 1:100 dilution; 5 μg of protein/ml. At the time that the TFL-007s was added, cytokine combo and anti-CD40 antibody were not added. In all panels, the mean fluorescent intensity (MFI) of the alloantibody secretion is compared between medium control and treatment with monoclonal antibody (mAb) TFL-007s. (a) Effects of mAb TFL-007s on the secretion of the primary alloantibody directed against DRB1*0101. (b–f) Effects of mAb TFL-007s on the secretion of the secondary alloantibodies (b) DRB1*0102; (c) DRB1*0404; (d) DRB1*0405; (e) DRB1*1402; (f) DRB1*0401). The mAb TFL-007s inhibited most significantly the primary alloantibody (P² < 0·0001), and also significantly inhibited the secretion of secondary alloantibodies. It is important to note that the ability of TFL-007s to inhibit secretion of primary antibody is highly significant and much greater than that of intravenous (IV)Ig. The mAb TFL-007s had a similar high ability to inhibit all the secondary alloantibodies, a feature that puts TFL-007s in stark contrast to the effect of IVIg on antibody secretion.